Literature DB >> 9473928

Type I collagen as a marker of bone metabolism in sickle cell hemoglobinopathies.

D M Bolarin1, P Swerdlow, A M Wallace, L Littsey.   

Abstract

Avascular necrosis of the skeletal system is a complication of sickle cell hemoglobinopathies. Type I collagen, which is synthesized by osteoblasts, comprises about 90% of the total organic matrix of bone. This preliminary study of skeletal changes in sickle cell hemoglobinopathies measured type I collagen formation and degradation using specific radioimmunoassays to determine the plasma concentrations of carboxyterminal propeptide of type I procollagen (PICP) and carboxyterminal pyridinoline cross-linked telopeptide of type I collagen (ICTP), respectively. Plasma ICTP concentrations were increased significantly in sickle cell patients with no clinical or radiologic symptoms of bone complications than in controls. Mean plasma ICTP concentration was moderately high in all patients. Plasma PICP levels did not differ significantly between patients and controls. This preliminary results indicate that measurements of plasma ICTP might be helpful in predicting bone changes in sickle cell hemoglobinopathies and also useful in the early detection of skeletal complications of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9473928      PMCID: PMC2608298     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  23 in total

Review 1.  Biochemical markers of bone turnover. A review.

Authors:  K Akesson
Journal:  Acta Orthop Scand       Date:  1995-08

2.  Marrow infarction in sickle cell anemia: correlation with marrow type and distribution by MRI.

Authors:  V M Rao; D G Mitchell; M D Rifkin; R M Steiner; D L Burk; D Levy; S K Ballas
Journal:  Magn Reson Imaging       Date:  1989 Jan-Feb       Impact factor: 2.546

3.  Collagen heterogeneity in normal human bone marrow.

Authors:  S A Bentley; O Alabaster; J M Foidart
Journal:  Br J Haematol       Date:  1981-06       Impact factor: 6.998

4.  Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.

Authors:  M Heikinheimo; R Halila; A Fasth
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

5.  Bone scan in sickle cell crisis.

Authors:  A Sain; R Sham; L Silver
Journal:  Clin Nucl Med       Date:  1978-03       Impact factor: 7.794

6.  Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis.

Authors:  M Apaja-Sarkkinen; H Autio-Harmainen; M Alavaikko; J Risteli; L Risteli
Journal:  Br J Haematol       Date:  1986-07       Impact factor: 6.998

7.  Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy.

Authors:  H Hasselbalch; P Junker; K Hørslev-Petersen; I Lisse; K D Bentsen
Journal:  Am J Hematol       Date:  1990-01       Impact factor: 10.047

8.  Osteonecrosis of the humeral head in sickle cell disease.

Authors:  P F Milner; A P Kraus; J I Sebes; L A Sleeper; K A Dukes; S H Embury; R Bellevue; M Koshy; J W Moohr; J Smith
Journal:  Clin Orthop Relat Res       Date:  1993-04       Impact factor: 4.176

9.  Biochemical markers of bone turnover in patients with metastatic bone disease.

Authors:  L M Demers; L Costa; V M Chinchilli; L Gaydos; E Curley; A Lipton
Journal:  Clin Chem       Date:  1995-10       Impact factor: 8.327

10.  Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP).

Authors:  T Taube; K Franssila; L Risteli; J Risteli; I Elomaa
Journal:  Br J Haematol       Date:  1992-09       Impact factor: 6.998

View more
  2 in total

1.  Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results.

Authors:  Oyebimpe O Adesina; James G Gurney; Guolian Kang; Martha Villavicencio; Jason R Hodges; Wassim Chemaitilly; Sue C Kaste; Babette S Zemel; Jane S Hankins
Journal:  Blood Adv       Date:  2019-05-14

2.  Aged bone matrix-derived extracellular vesicles as a messenger for calcification paradox.

Authors:  Zhen-Xing Wang; Zhong-Wei Luo; Fu-Xing-Zi Li; Jia Cao; Shan-Shan Rao; Yi-Wei Liu; Yi-Yi Wang; Guo-Qiang Zhu; Jiang-Shan Gong; Jing-Tao Zou; Qiang Wang; Yi-Juan Tan; Yan Zhang; Yin Hu; You-You Li; Hao Yin; Xiao-Kai Wang; Ze-Hui He; Lu Ren; Zheng-Zhao Liu; Xiong-Ke Hu; Ling-Qing Yuan; Ran Xu; Chun-Yuan Chen; Hui Xie
Journal:  Nat Commun       Date:  2022-03-18       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.